GlassScriptPhysician profile
Shunai Jiang
NPI 1265570840
$4,692.88
in general payments reported to CMS, 2019-2025
24 companies · $513 in 2025
The $513 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,222 · 2020: $504 · 2021: $433 · 2022: $336 · 2023: $603 · 2024: $1,081 · 2025: $513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,197.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $977.53 | 2019-2025 | Radius, Idosetr, Idose |
| Allergan, INC. | $691.83 | 2019-2022 | |
| Abbvie INC. | $626.87 | 2022-2025 | |
| Alcon Vision LLC | $502.17 | 2019-2025 | Argos, Rocklatan, Clareon |
| Akorn, INC. | $218.28 | 2019-2020 | |
| New World Medical,INC. | $173.95 | 2019-2024 | Clearpath, Streamline, Kahook Dual Blade |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $164.02 | 2019-2021 | |
| Sight Sciences, INC. | $148.71 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Bausch & Lomb Americas INC. | $147.39 | 2022-2025 | Miebo, Vyzulta |
| Sun Pharmaceutical Industries INC. | $147.17 | 2019-2020 | |
| Akorn Operating Company LLC | $137.16 | 2021 | |
| Harrow Eye, LLC | $113.15 | 2024-2025 | Vevye |
| Aerie Pharmaceuticals, INC. | $107.73 | 2019-2021 | |
| Ocular Therapeutix, INC. | $80.30 | 2019 | |
| Novartis Pharmaceuticals Corporation | $78.52 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $77.34 | 2023-2025 | Iyuzeh |
| Oyster Point Pharma, INC. | $73.99 | 2023-2025 | Tyrvaya |
| Johnson & Johnson Surgical Vision, INC. | $72.27 | 2019-2022 | |
| Amgen INC. | $51.76 | 2024-2025 | Tepezza |
| Nova Eye, INC. | $30.82 | 2024 | |
| Kala Pharmaceuticals, INC. | $29.53 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $22.72 | 2024 | Xdemvy |
| Ivantis, INC | $19.67 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shunai Jiang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.